Datasheet

Version: 3.0.0 Revision date: 29 Aug 2025



Sorbitol Dehydrogenase (SORD) Antibody

Catalogue No.:abx028557



Sorbitol dehydrogenase (SORD; EC 1.1.1.14) catalyzes the interconversion of polyols and their corresponding ketoses, and together with aldose reductase (ALDR1; MIM 103880), makes up the sorbitol pathway that is believed to play an important role in the development of diabetic complications (summarized by Carr and Markham, 1995 [PubMed 8535074]). The first reaction of the pathway (also called the polyol pathway) is the reduction of glucose to sorbitol by ALDR1 with NADPH as the cofactor. SORD then oxidizes the sorbitol to fructose using NAD (+) cofactor.

Target: Sorbitol Dehydrogenase (SORD)

Clonality: Polyclonal

Reactivity: Human

Tested Applications: ELISA, WB

Host: Rabbit

Recommended dilutions: WB: 1/1000. Optimal dilutions/concentrations should be determined by the end user.

Conjugation: Unconjugated

Immunogen: KLH-conjugated synthetic peptide between 211-239 amino acids from the Central region of human

SORD.

Isotype: IgG

Form: Liquid

Purification: Purified through a protein A column, followed by peptide affinity purification.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

UniProt Primary AC: Q00796 (UniProt, ExPASy)

1 of 2

Datasheet

Version: 3.0.0 Revision date: 29 Aug 2025



KEGG: hsa:6652

String: <u>9606.ENSP00000267814</u>

Molecular Weight: Calculated MW: 38.3 kDa

Buffer: PBS containing 0.09% sodium azide.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC.

THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL

CONSUMPTION.